Satish Tripathi, PhD, MPH
President and Chair, Board of Directors, Ek Kadam Aur
Vice President, Global Regulatory Affairs, Avexis (A Novartis Company)
Dr Tripathi founded Ek Kadam Aur in the United States in 2015 and in India in 2017.Dr. Tripathi is a bio-pharmaceutical leader and global influencer, with over 25 years of experience in the development and implementation of worldwide regulatory strategies in the development of new medicines, biotechnology products, medical devices, generic drugs and biosimilars.
Dr. Tripathi worked as a Reviewer of New Drug applications with the US Food & Drug Administration’s Oncology and Pulmonary divisions, and thereafter with multiple global bio-pharma corporations such as Baxter Healthcare, Pfizer, Johnson & Johnson, Roche-Genentech, Ophthotech and Biomedical Consulting International. Currently, Dr Tripathi is Vice President with AveXis, a Novartis company, where he is responsible for Global Regulatory Affairs, Clinical Trial Regulatory and Regulatory Pharmacology/Toxicology aspects of development and global registration of gene therapy products.
As a thought leader in drug discovery and development, Dr Tripathi has published numerous manuscripts, reviews and conference abstracts globally. With a special interest in biosimilars, he has presented at the FDA’s Public Hearing on Biosimilars.
Through his experience in healthcare, Dr. Tripathi brings a legion of positive energy and guidance to the Ek Kadam Aur Team as this nonprofit public charitable organization moves forward with its programs and projects in education and community health.
An alumnus of Columbia University, Massachusetts Institute of Technology and University of Glasgow, Dr. Tripathi has been passionate about the upliftment and empowerment of underprivileged children ever since he founded Ek Kadam Aur. In addition, he has been significantly contributing to pharmaceutical education in India and the United States.